This sBLA submission is supported by clinical, pre-clinical, and manufacturing data demonstrating the safety, tolerability, and immunogenicity of the bivalent vaccine.
The company has reported total income of Rs. 691.9 crores during the quarter ended December 31, 2022
More than 5 lakh patients availed the benefit of queue-less OPD registration using this service
Ayurveda is one of the most advanced sciences of its times
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
A total of 889 M&A deals were announced in the medical devices sector in 2022 worth $93 billion
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
Subscribe To Our Newsletter & Stay Updated
